Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan. Lanadelumab subcutaneous injection
The post Takeda submits New Drug Application for lanadelumab in Japan appeared first on Pharmaceutical Business review.
This is not a CAPTIS article. Originally, it was published here.